期刊文献+

携带人Oct4和EGFP基因慢病毒表达载体构建 被引量:2

Construction of A Lentiviral Expression Vector Harboring Human Oct4 and EGFP Genes
原文传递
导出
摘要 目的构建携带人Oct4和EGFP基因的慢病毒表达载体pFUOGW。方法SacⅡ线性化pLenti-EF1a-Oct4-IRES-EGFP,回收片段并补平SacⅡ切口,接着BamHⅠ酶切该片段,回收2.565kb片段而获连接用Oct4-IRES-EGFP;EcoRⅠ线性化pFUGW,回收并补平EcoRⅠ切口,然后BamHⅠ酶切该片段,回收9.174kb片段获连接用载体片段,最后使用DNA连接试剂盒(TaKaRa)中的SolutionⅠ将其与连接用Oct4-IRES-EGFP连接,连接产物转化,次日挑选单菌落,提取质粒并行酶切鉴定。所构建载体命名为pFUOGW。获pFUOGW后,按Invitrogen公司推荐的标准程序进行慢病毒包装和确认慢病毒是否成功生产;携带Oct4和EGFP基因的慢病毒感染293FT细胞和鼻咽癌细胞株C666-1、CNE1和6-10B以建立相应病毒感染体系。结果酶切鉴定证实成功构建了pFUOGW,按标准程序生产的携带Oct4和EGFP基因的慢病毒上清高效率感染鼻咽癌细胞株C666-1、CNE1和6-10B。结论成功构建携带人Oct4和EGFP基因的慢病毒表达载体pFUOGW,为相关后续的研究打下良好的基础。 Objective To generate lentiviral expression vectors harboring human Oct4 gene and EGFP gene.Methods Oct4-IRES-EGFP was obtained from pLenti-EF1a-Oct4-IRES-EGFP by digestion with SacⅡ,blunted at SacⅡ site,and then by digestion with BamHⅠ,and subsequently directionally cloned into the restriction sites EcoR Ⅰ(blunted at EcoRⅠ site) and BamHⅠ of the lentiviral vector pFUGW after EGFP gene was released from pFUGW by digestion with EcoRⅠ,blunted at EcoRⅠ site,and then by digestion with BamHⅠ,designated pFUOGW,as verified by enzyme digestion.According to the standard protocol from Invitrogen,lentiviruses were produced,followed by confirmation using EGFP assay under fluorescent microscope after infecting 293FT cells.Lentiviruses harboring Oct4 and EGFP genes were employed to infect human nasopharyngeal carcinoma cells(i.e.,C666-1,CNE-1 and 6-10B).Results pFUOGW was successfully generated.Lentivirus supernatant harboring Oct4 and EGFP genes efficiently infected C666-1,CNE-1 and 6-10B.Conclusion The lentiviral expression vector harboring human Oct4 gene and EGFP gene was successfully constructed.
出处 《热带医学杂志》 CAS 2010年第3期238-240,F0004,共4页 Journal of Tropical Medicine
基金 国家自然科学基金委员会-广东省联合基金重点项目(No.u0732006) 国家自然科学基金(No.30271177) 广东省自然科学基金(No.021903 No.9151063101000015) 广东省卫生厅基金(No.A2007359) 南方医科大学优秀中青年科技人才库科研资助金 广州地区科学仪器协作共用网专用基金(No.2006176)
关键词 OCT4 EGFP 慢病毒载体 Oct4 EGFP lentivirus vector
  • 相关文献

参考文献4

二级参考文献28

  • 1Huayu Qi,Duanqing Pei, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510663, China pei_duanqing@gibh.ac.cn.The magic of four: induction of pluripotent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4[J].Cell Research,2007,17(7):578-580. 被引量:12
  • 2Stegmeier F, Hu G, Rickles R J, et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells [J]. Proc Natl Acad Sci USA, 2005, 102(37) : 13212-13217.
  • 3Ventura A, Meissner A, Dillon CP, et al. Cre-lox-regulated conditional RNA interference from transgenes [J]. Proc Natl Acad Sci USA, 2004, 101(28) : 10380-10385.
  • 4Hofmann MC, Braydich-Stolle L, Dettin L, et al. Immortalization of mouse germ line stem cells [J]. Stem Cells, 2005, 23(2): 200-510.
  • 5Dann CT, Garbers DL. Production of knockdown rats by lentiviral transduction of embryos with short hairpin RNA transgenes [ J ]. Methods Mol Biol, 2008, 450 : 193-209.
  • 6Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors[J]. Science, 2002, 295(5556):868-872.
  • 7Park F. Lentiviral vectors: are they the future of animal transgenesis[J]? Physiol Genomics, 2007, 31(2) : 159-173.
  • 8Singer O, Tiscornia G, Ikawa M, et al. Rapid generation of knockdown transgenic mice by silencing lentiviral vectors [J]. Nat Protoc, 2006, 1 (1) : 286-292.
  • 9Looijenga LH,Stoop H,De Leeuw HP,et al.POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors[J].Cancer research,2003,63 (9)::2244-2250.
  • 10Gupta S,Verfaillie C,Chmielewski D,et al.Isolation and Characterization of Kidney-Derived Stem Cells[J].J Am Soc Nephrol,2006,23(2):20.

共引文献99

同被引文献19

  • 1高海德,路平,鲁阳,庞葵,徐惠绵,王舒宝,陈峻青,赵实诚.双突变二氢叶酸还原酶基因对小鼠的化疗保护作用[J].中华肿瘤杂志,2006,28(8):583-585. 被引量:3
  • 2Gershoni-Baruch R, Dagan E, Israeli D, et al. Association of the C667T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women [J]. Eur J Cancer, 2000, 36 (18): 2313-2316.
  • 3Sierra E E, Goldman I D. Recent advances in the understanding of the mechanism of membrance transport of folates and antifolates [J]. Semin Oncol, 1999, 26(2): 11-23.
  • 4Gait J R, Halkar R K, Evans C O, et al. In vivo assay of folate receptors in nonfunctional pituitary adenomas with 99mTc-folate SPECT/CT[J]. J Nucl Med, 2010, 51(11): 1716-1723.
  • 5Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications [J]. Ann NY Acad Sci, 2000, 922: 188-194.
  • 6Askari BS, Krajinovic M. Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes [J]. Curr Genomics, 2010,11(8): 578-583.
  • 7Li L, Luan Y, Li X, et al. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis [J]. Oncol Rep, 2005, 13(5): 793-799.
  • 8Levy AS, Sather HN, Steinherz PG, et al. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study [J]. J Pediatr Hematol Oncol, 2003,25(9): 688-695.
  • 9Webber S, Bartlett CA, Boritzki TJ, et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies [J]. Cancer Chemother Pharmacol, 1996,37(6): 509-517.
  • 10Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD SCID mice by HIV vectors[J]. Science, 1999, 283(5402): 682-686.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部